MOG and experimental autoimmune encephalomyelitis: Remibrutinib was evaluated in the myelin oligodendrocyte glycoprotein (MOG)35-55 model of experimental autoimmune encephalomyelitis (EAE) and in the lysolecithin model of demyelination.